{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:27:09Z","timestamp":1779377229444,"version":"3.53.1"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.lfs.2025.123376","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:53:01Z","timestamp":1736304781000},"page":"123376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Deciphering the role of neuropeptides as biomarkers for early diagnosis of Parkinson's disease"],"prefix":"10.1016","volume":"363","author":[{"given":"Jhanvi","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Godad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2025.123376_bb0005","series-title":"Epidemiology and Associated Risk Factors of Parkinson\u2019s Disease Among the North Indian Population","author":"S.","year":"2016"},{"key":"10.1016\/j.lfs.2025.123376_bb0010","first-page":"S1","article-title":"Pharmacological management of Parkinson\u2019s disease motor symptoms: update and recommendations from an expert","volume":"75","author":"Kulisevsky","year":"2022","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.lfs.2025.123376_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","article-title":"Signaling pathways in Parkinson\u2019s disease: molecular mechanisms and therapeutic interventions","volume":"8","author":"Dong-Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2025.123376_bb0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mds.23795","article-title":"Neuropathology of sporadic Parkinson\u2019s disease: evaluation and changes of concepts","volume":"27","author":"Jellinger","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.lfs.2025.123376_bb0025","series-title":"Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis","author":"Kouli","year":"2018"},{"key":"10.1016\/j.lfs.2025.123376_bb0030","series-title":"Challenges in Diagnosis of Parkinson Disease","author":"P.","year":"2021"},{"key":"10.1016\/j.lfs.2025.123376_bb0035","series-title":"Epidemiology of Parkinson Disease","author":"Tysnes","year":"2017"},{"key":"10.1016\/j.lfs.2025.123376_bb0040","series-title":"Prevalence of Parkinson\u2019s Disease Across North America","author":"A.W.W. & C.T. on behalf of the P.F.P.G. C. Marras","year":"2018"},{"key":"10.1016\/j.lfs.2025.123376_bb0045","series-title":"Burden of Parkinson Disease in China, 1990\u20132019: Findings From the 2019 Global Burden of Disease Study","author":"Z.","year":"2023"},{"key":"10.1016\/j.lfs.2025.123376_bb0050","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson\u2019s disease","volume":"139","author":"Sveinbjornsdottir","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2025.123376_bb0055","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2025.123376_bb0060","series-title":"Current Understanding of the Molecular Mechanisms in Parkinson\u2019s Disease: Targets for Potential Treatments","author":"M.","year":"2017"},{"key":"10.1016\/j.lfs.2025.123376_bb0065","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/mds.21521","article-title":"The unified Parkinson\u2019s disease rating scale: validation study of the mentation, behavior, and mood section","volume":"22","author":"Starkstein","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.lfs.2025.123376_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011234","article-title":"Dopamine transporter imaging, current status of a potential biomarker: a comprehensive review","volume":"22","author":"Palermo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123376_bb0075","first-page":"353","article-title":"The role of neuroimaging in the early diagnosis and evaluation of Parkinson\u2019s disease","volume":"96","author":"Seibyl","year":"2005","journal-title":"Minerva Med."},{"key":"10.1016\/j.lfs.2025.123376_bb0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","article-title":"High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease","volume":"9","author":"Russo","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.lfs.2025.123376_bb0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/mds.27888","article-title":"Blood biomarkers with Parkinson\u2019s disease clusters and prognosis: the Oxford discovery cohort","volume":"35","author":"Lawton","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.lfs.2025.123376_bb0090","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.parkreldis.2020.02.015","article-title":"New generation genetic testing entering the clinic","volume":"73","author":"Gorcenco","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.lfs.2025.123376_bb0095","article-title":"Associations between olfactory impairment and cognitive functions in patients with Parkinson disease","author":"Pekel","year":"2018","journal-title":"Archives Neuropsychiatry"},{"key":"10.1016\/j.lfs.2025.123376_bb0100","series-title":"Olfaction as an Early Marker of Parkinson\u2019s Disease and Alzheimer\u2019s Disease","first-page":"317","author":"Walker","year":"2021"},{"key":"10.1016\/j.lfs.2025.123376_bb0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.lfs.2025.123376_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.01328","article-title":"The challenge and opportunity to diagnose Parkinson\u2019s disease in midlife","volume":"10","author":"Kilzheimer","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.lfs.2025.123376_bb0115","series-title":"Current Challenges in Detection of Parkinson\u2019s Disease","author":"G.","year":"2020"},{"key":"10.1016\/j.lfs.2025.123376_bb0120","series-title":"What Are Neuropeptides?","author":"Burbach","year":"2011"},{"key":"10.1016\/j.lfs.2025.123376_bb0125","series-title":"Neuropeptide Transmission in Brain Circuits","author":"van den Pol","year":"2012"},{"key":"10.1016\/j.lfs.2025.123376_bb0130","article-title":"Evolution of neuropeptide signalling systems","volume":"2018","author":"L.","year":"2018","journal-title":"J. Exp. Biol."},{"key":"10.1016\/j.lfs.2025.123376_bb0135","article-title":"Neuropeptides: roles and activities as metal chelators in neurodegenerative diseases","volume":"2021","author":"M.","year":"2021","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.lfs.2025.123376_bb0140","article-title":"Neuropeptides and behaviors: how small peptides regulate nervous system function and behavioral outputs","volume":"2021","author":"B.","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.lfs.2025.123376_bb0145","series-title":"Peptides","article-title":"Parkinson disease: protective role and function of neuropeptides","volume":"vol. 151","author":"Tabikh","year":"2022"},{"key":"10.1016\/j.lfs.2025.123376_bb0150","series-title":"Demystifying the Neuroprotective Role of Neuropeptides in Parkinson\u2019s Disease: A Newfangled and Eloquent Therapeutic Perspective","author":"M.M.","year":"2022"},{"key":"10.1016\/j.lfs.2025.123376_bb0155","series-title":"Recent Advances in Biomarkers for Parkinson\u2019s Disease","author":"S.","year":"2018"},{"key":"10.1016\/j.lfs.2025.123376_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/1735-1995.181989","article-title":"Alpha-synuclein structure, functions, and interactions","volume":"21","author":"Emamzadeh","year":"2016","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.lfs.2025.123376_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.01399","article-title":"Alpha-synuclein physiology and pathology: a perspective on cellular structures and organelles","volume":"13","author":"Bernal-Conde","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.lfs.2025.123376_bb0170","series-title":"Monitoring \u03b1-Synuclein Aggregation","author":"B.","year":"2023"},{"key":"10.1016\/j.lfs.2025.123376_bb0175","series-title":"Alpha-synuclein Aggregation Pathway in Parkinson\u2019s Disease: Current Status and Novel Therapeutic Approaches","author":"R.","year":"2022"},{"key":"10.1016\/j.lfs.2025.123376_bb0180","series-title":"Alpha-synuclein as a Biomarker for Parkinson\u2019s Disease","author":"Z.","year":"2016"},{"key":"10.1016\/j.lfs.2025.123376_bb0185","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/ijms23020750","article-title":"The regenerative potential of substance P","volume":"23","author":"Redkiewicz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123376_bb0190","series-title":"Substance P","author":"G.","year":"2001"},{"key":"10.1016\/j.lfs.2025.123376_bb0195","series-title":"Substance P and Its Tachykinin NK1 Receptor: A Novel Neuroprotective Target for Parkinson\u2019s Disease","author":"V.","year":"2015"},{"key":"10.1016\/j.lfs.2025.123376_bb0200","series-title":"Substance P: Structure, Function, and Therapeutics","author":"Datar","year":"2004"},{"key":"10.1016\/j.lfs.2025.123376_bb0205","doi-asserted-by":"crossref","first-page":"12490","DOI":"10.1523\/JNEUROSCI.2238-14.2014","article-title":"Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase","volume":"34","author":"Wang","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2025.123376_bb0210","series-title":"The Role of the Neuropeptide Substance P in the Pathogenesis of Parkinson\u2019s Disease","author":"V.","year":"2012"},{"key":"10.1016\/j.lfs.2025.123376_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2024.107540","article-title":"Hungry for relief: potential for neurotensin to address comorbid obesity and pain","author":"Khan","year":"2024","journal-title":"Appetite"},{"key":"10.1016\/j.lfs.2025.123376_bb0220","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2174\/1570159X21666230803101629","article-title":"Neurotensin and neurotensin receptors in stress-related disorders: pathophysiology & novel drug targets","volume":"22","author":"Kyriatzis","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.lfs.2025.123376_bb0225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000527872","article-title":"Neurotensin-binding immunoglobulin G in patients with Parkinson\u2019s disease","volume":"30","author":"Muruzheva","year":"2023","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.lfs.2025.123376_bb0230","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/archneur.61.5.641","article-title":"The neurobiology of dopamine signaling","volume":"61","author":"Girault","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.lfs.2025.123376_bb0235","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1749-6632.1992.tb27345.x","article-title":"Actions of neurotensin: a review of the electrophysiological studies","volume":"668","author":"Shi","year":"1992","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.lfs.2025.123376_bb0240","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1038\/sj.npp.1300134","article-title":"Cellular and behavioral effects of D2 dopamine receptor hydrophobic eigenmode-targeted peptide ligands","volume":"28","author":"Mandell","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lfs.2025.123376_bb0245","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0006-8993(91)90675-L","article-title":"Compartments in rat dorsal and ventral striatum revealed following injection of 6-hydroxydopamine into the ventral mesencephalon","volume":"552","author":"Zahm","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2025.123376_bb0250","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2202-10-96","article-title":"Presynaptic action of neurotensin on dopamine release through inhibition of D2 receptor function","volume":"10","author":"Fawaz","year":"2009","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.lfs.2025.123376_bb0255","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0028-3908(89)90194-9","article-title":"Electrophysiological effects of neurotensin on dopaminergic neurones of the ventral tegmental area of the rat in vitro","volume":"28","author":"Seutin","year":"1989","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2025.123376_bb0260","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0006-8993(89)90523-4","article-title":"Substance P, neurotensin and enkephalin injections into the ventral tegmental area: comparative study on dopamine turnover in several forebrain structures","volume":"486","author":"Cador","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2025.123376_bb0265","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1139\/jpn.0627","article-title":"The role of neurotensin in central nervous system pathophysiology: what is the evidence?","volume":"31","author":"St-Gelais","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.lfs.2025.123376_bb0270","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0006-8993(91)90428-X","article-title":"Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats","volume":"538","author":"Jolicoeur","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2025.123376_bb0275","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0028-3908(91)90041-9","article-title":"Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat","volume":"30","author":"Rivest","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2025.123376_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310932","article-title":"Brain-biomarker changes in body fluids of patients with Parkinson\u2019s disease","volume":"24","author":"Cocco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123376_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2013.00036","article-title":"Diverse roles of neurotensin agonists in the central nervous system","volume":"4","author":"Boules","year":"2013","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.lfs.2025.123376_bb0290","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.peptides.2006.04.024","article-title":"Neurotensin: role in psychiatric and neurological diseases","volume":"27","author":"C\u00e1ceda","year":"2006","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.lfs.2025.123376_bb0295","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.npep.2015.09.008","article-title":"Neuropeptide Y: a stressful review","volume":"55","author":"Reichmann","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.lfs.2025.123376_bb0300","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.nbd.2016.07.022","article-title":"Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases","volume":"95","author":"Duarte-Neves","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.lfs.2025.123376_bb0305","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.neurobiolaging.2011.06.018","article-title":"Neuroprotection by neuropeptide Y in cell and animal models of Parkinson\u2019s disease","volume":"33","author":"Decressac","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.lfs.2025.123376_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.652363","article-title":"Versatile functions of somatostatin and somatostatin receptors in the gastrointestinal system","volume":"12","author":"Shamsi","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.lfs.2025.123376_bb0315","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s12276-021-00580-4","article-title":"The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders","volume":"53","author":"Song","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lfs.2025.123376_bb0320","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/biom12020312","article-title":"Somatostatin and somatostatin-containing interneurons\u2014from plasticity to pathology","volume":"12","author":"Liguz-Lecznar","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.lfs.2025.123376_bb0325","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.3390\/ijms22115864","article-title":"Somatostatin, a presynaptic modulator of glutamatergic signal in the central nervous system","volume":"22","author":"Pittaluga","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123376_bb0330","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1152\/jn.00244.2012","article-title":"Presynaptic modulation by somatostatin in the rat neostriatum is altered in a model of parkinsonism","volume":"108","author":"L\u00f3pez-Huerta","year":"2012","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.lfs.2025.123376_bb0335","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.3390\/ijms23094565","article-title":"Demystifying the neuroprotective role of neuropeptides in Parkinson\u2019s disease: a newfangled and eloquent therapeutic perspective","volume":"23","author":"Behl","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123376_bb0340","series-title":"Detection of Elevated Levels of \u03b1-Synuclein Oligomers in CSF From Patients With Parkinson Disease","author":"Tokuda","year":"2010"},{"key":"10.1016\/j.lfs.2025.123376_bb0345","series-title":"\u03b1-Synuclein and Tau Concentrations in Cerebrospinal Fluid of Patients Presenting With Parkinsonism: A Cohort Study","author":"Mollenhauer","year":"2011"},{"key":"10.1016\/j.lfs.2025.123376_bb0350","series-title":"Cerebrospinal Fluid Lysosomal Enzymes and Alpha-synuclein in Parkinson\u2019s Disease","author":"Parnetti","year":"2014"},{"key":"10.1016\/j.lfs.2025.123376_bb0355","series-title":"DJ-1 and \u03b1-Synuclein in Human Cerebrospinal Fluid as Biomarkers of Parkinson\u2019s Disease","author":"Z.","year":"2010"},{"key":"10.1016\/j.lfs.2025.123376_bb0360","series-title":"Detection of -Synuclein Oligomers in Red Blood Cells as a Potential Biomarker of Parkinson\u2019s Disease","author":"F.","year":"2015"},{"key":"10.1016\/j.lfs.2025.123376_bb0365","series-title":"Detection of Neuron-derived Pathological \u03b1-Synuclein in Blood","author":"Z.","year":"2022"},{"key":"10.1016\/j.lfs.2025.123376_bb0370","series-title":"Plasma and Serum Alpha-synuclein as a Biomarker in Parkinson\u2019s Disease: A Meta-analysis","author":"M.-G.","year":"2022"},{"key":"10.1016\/j.lfs.2025.123376_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151156","article-title":"Abnormal salivary total and oligomeric alpha-synuclein in Parkinson\u2019s disease","volume":"11","author":"Vivacqua","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2025.123376_bb0380","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.parkreldis.2019.02.014","article-title":"Salivary alpha-synuclein in the diagnosis of Parkinson\u2019s disease and progressive supranuclear palsy","volume":"63","author":"Vivacqua","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.lfs.2025.123376_bb0385","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1038\/s41598-020-65503-1","article-title":"Increased alpha-synuclein tear fluid levels in patients with Parkinson\u2019s disease","volume":"10","author":"Maass","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2025.123376_bb0390","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2217\/bmm-2019-0315","article-title":"Levels of oligomeric \u03b1-synuclein in reflex tears distinguish Parkinson\u2019s disease patients from healthy controls","volume":"13","author":"Hamm-Alvarez","year":"2019","journal-title":"Biomark. Med"},{"key":"10.1016\/j.lfs.2025.123376_bb0395","series-title":"Tear Proteins as Possible Biomarkers for Parkinson\u2019s Disease, ARVO Annual Meeting Abstract","author":"S.F.H.-A.M.L.D.F.S.R.J.M.S.D.F.B.C.R.G.W.M.C. Okamoto","year":"2018"},{"key":"10.1016\/j.lfs.2025.123376_bb0400","series-title":"Detection and Assessment of \u03b1-Synuclein Oligomers in the Urine of Parkinson\u2019s Disease Patients","author":"H.","year":"2020"},{"key":"10.1016\/j.lfs.2025.123376_bb0405","series-title":"Analysis of \u03b1-Synuclein Levels Related to LRRK2 Kinase Activity: From Substantia Nigra to Urine of Patients With Parkinson\u2019s Disease","author":"S.","year":"2021"},{"key":"10.1016\/j.lfs.2025.123376_bb0410","doi-asserted-by":"crossref","DOI":"10.1002\/alz.043249","article-title":"Developing a novel alpha-synuclein positron emission tomography (PET) tracer for the diagnosis of synucleinopathies","volume":"16","author":"Capotosti","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.lfs.2025.123376_bb0415","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","article-title":"Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies","volume":"186","author":"Xiang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2025.123376_bb0420","series-title":"Neurobiology of Cerebrospinal Fluid 2","first-page":"67","article-title":"Substance P in human cerebrospinal fluid","author":"Nutt","year":"1983"},{"key":"10.1016\/j.lfs.2025.123376_bb0425","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0143-4179(91)90002-Z","article-title":"Ventricular fluid neuropeptides in Parkinson\u2019s disease. II. Levels of substance P-like immunoreactivity","volume":"18","author":"Cramer","year":"1991","journal-title":"Neuropeptides"},{"key":"10.1016\/j.lfs.2025.123376_bb0430","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2974\/kmj1951.40.287","article-title":"Somatostatin and substance p in the cerebrospinal fluid of some neurodegenerative disorders","volume":"40","author":"Harigaya","year":"1990","journal-title":"KITAKANTO Med. J."},{"key":"10.1016\/j.lfs.2025.123376_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/3555418","article-title":"Salivary biomarkers: noninvasive ways for diagnosis of Parkinson\u2019s disease","volume":"2023","author":"Salaramoli","year":"2023","journal-title":"Neurol. Res. Int."},{"key":"10.1016\/j.lfs.2025.123376_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00386","article-title":"Substance P saliva reduction predicts pharyngeal dysphagia in Parkinson\u2019s disease","volume":"10","author":"Schr\u00f6der","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.lfs.2025.123376_bb0455","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/bms.1200230407","article-title":"Characterization of neurotensin-like immunoreactivity in human cerebrospinal fluid by high-performance liquid chromatography combined with mass spectrometry","volume":"23","author":"Eriksson","year":"1994","journal-title":"Biol. Mass Spectrom."},{"key":"10.1016\/j.lfs.2025.123376_bb0460","series-title":"The Role of Neurotensin in Central Nervous System Pathophysiology: What Is the Evidence?","author":"J.","year":"2006"},{"key":"10.1016\/j.lfs.2025.123376_bb0465","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/brain\/119.3.823","article-title":"Alterations in peptide levels in Parkinson\u2019s disease and incidental Lewy body disease","volume":"119","author":"Fernandez","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.lfs.2025.123376_bb0470","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/jnnp.70.6.784","article-title":"Increased plasma neurotensin concentrations in patients with Parkinson\u2019s disease","volume":"70","author":"Schimpff","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.lfs.2025.123376_bb0475","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000527872","article-title":"Neurotensin-binding immunoglobulin G in patients with Parkinson\u2019s disease","volume":"30","author":"Muruzheva","year":"2023","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.lfs.2025.123376_bb0480","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0014-4886(91)90080-V","article-title":"Decreased levels of [Met]enkephalin, neuropeptide Y, substance P, and vasoactive intestinal peptide in parkinsonian adrenal medulla","volume":"114","author":"Stoddard","year":"1991","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.lfs.2025.123376_bb0485","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF02260903","article-title":"Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson\u2019s disease, multiple system atrophy and dementia of the Alzheimer type","volume":"4","author":"Martignoni","year":"1992","journal-title":"J. Neural Transm. Park. Dis. Dement. Sect."},{"key":"10.1016\/j.lfs.2025.123376_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.646726","article-title":"The emerging role of neuropeptides in Parkinson\u2019s disease","volume":"13","author":"Zheng","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.lfs.2025.123376_bb0495","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1212\/WNL.32.3.312","article-title":"Low cerebrospinal fluid somatostatin in Parkinson disease","volume":"32","author":"Dupont","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.lfs.2025.123376_bb0500","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/jnnp.49.12.1374","article-title":"Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson\u2019s disease and its relation to dementia","volume":"49","author":"Jolkkonen","year":"1986","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.lfs.2025.123376_bb0505","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s12276-021-00580-4","article-title":"The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders","volume":"53","author":"Song","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lfs.2025.123376_bb0510","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0404.2009.01178.x","article-title":"Serum somatostatin in early-stage Parkinson\u2019s disease","volume":"121","author":"Shiraishi","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.lfs.2025.123376_bb0515","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.parkreldis.2014.01.011","article-title":"CSF \u03b1-synuclein and UCH-L1 levels in Parkinson\u2019s disease and atypical parkinsonian disorders","volume":"20","author":"Mondello","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.lfs.2025.123376_bb0520","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1093\/brain\/awr015","article-title":"Salivary \u03b1-synuclein and DJ-1: potential biomarkers for Parkinson\u2019s disease","volume":"134","author":"Devic","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.lfs.2025.123376_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710123","article-title":"Tear biomarkers in Alzheimer\u2019s and Parkinson\u2019s diseases, and multiple sclerosis: implications for diagnosis (systematic review)","volume":"23","author":"Kr\u00f3l-Grzyma\u0142a","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123376_bb0530","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/brain\/awh054","article-title":"The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson\u2019s disease","volume":"127","author":"Bandopadhyay","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.lfs.2025.123376_bb0535","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00702-023-02632-7","article-title":"Blood neurofilament light chain in Parkinson\u2019s disease","volume":"130","author":"Buhmann","year":"2023","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.lfs.2025.123376_bb0540","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00809","article-title":"Tau pathology in Parkinson\u2019s disease","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.lfs.2025.123376_bb0545","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00207454.2014.961454","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson\u2019s disease diagnosis: a systematic review and meta-analysis","volume":"125","author":"Gao","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.lfs.2025.123376_bb0550","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/srep02540","article-title":"A longitudinal study on \u03b1-synuclein in blood plasma as a biomarker for Parkinson\u2019s disease","volume":"3","author":"Foulds","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2025.123376_bb0555","article-title":"Salivary total \u03b1-synuclein, oligomeric \u03b1-synuclein and SNCA variants in Parkinson\u2019s disease patients","volume":"6","author":"Kang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2025.123376_bb0560","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1038\/s41598-020-65503-1","article-title":"Increased alpha-synuclein tear fluid levels in patients with Parkinson\u2019s disease","volume":"10","author":"Maass","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2025.123376_bb0565","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3233\/JPD-201983","article-title":"Detection and assessment of \u03b1-synuclein oligomers in the urine of Parkinson\u2019s disease patients","volume":"10","author":"Nam","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.lfs.2025.123376_bb0570","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13167-016-0065-3","article-title":"Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine","volume":"7","author":"Hagan","year":"2016","journal-title":"EPMA J."},{"key":"10.1016\/j.lfs.2025.123376_bb0575","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.peptides.2006.04.024","article-title":"Neurotensin: role in psychiatric and neurological diseases","volume":"27","author":"C\u00e1ceda","year":"2006","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.lfs.2025.123376_bb0580","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.npep.2015.09.008","article-title":"Neuropeptide Y: a stressful review","volume":"55","author":"Reichmann","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.lfs.2025.123376_bb0585","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13578-021-00657-7","article-title":"Regulation of neuropeptide Y in body microenvironments and its potential application in therapies: a review","volume":"11","author":"Zhang","year":"2021","journal-title":"Cell Biosci."},{"key":"10.1016\/j.lfs.2025.123376_bb0590","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0404.2009.01178.x","article-title":"Serum somatostatin in early-stage Parkinson\u2019s disease","volume":"121","author":"Shiraishi","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.lfs.2025.123376_bb0595","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF02259660","article-title":"CSF somatostatin increase in patients with early parkinsonian syndrome","volume":"9","author":"Espino","year":"1995","journal-title":"J. Neural Transm. Park. Dis. Dement. Sect."},{"key":"10.1016\/j.lfs.2025.123376_bb0600","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.01388","article-title":"Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson\u2019s disease","volume":"10","author":"Chang","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.lfs.2025.123376_bb0605","series-title":"DJ-1 as a Biomarker of Parkinson\u2019s Disease","first-page":"149","author":"Saito","year":"2017"},{"key":"10.1016\/j.lfs.2025.123376_bb0610","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/ijms25021303","article-title":"Ubiquitin carboxyl-terminal hydrolase L1 and its role in Parkinson\u2019s disease","volume":"25","author":"Buneeva","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123376_bb0615","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.3390\/ijms23084148","article-title":"Biomarker of neuroinflammation in Parkinson\u2019s disease","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123376_bb0620","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s12031-020-01776-5","article-title":"Tau in the pathophysiology of Parkinson\u2019s disease","volume":"71","author":"Pan","year":"2021","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.lfs.2025.123376_bb0625","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00702-023-02632-7","article-title":"Blood neurofilament light chain in Parkinson\u2019s disease","volume":"130","author":"Buhmann","year":"2023","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.lfs.2025.123376_bb0630","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12916-023-03120-1","article-title":"Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson\u2019s disease: a prospective cohort study","volume":"21","author":"Lin","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.lfs.2025.123376_bb0635","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/15622975.2017.1375556","article-title":"Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry","volume":"19","author":"Lewczuk","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.lfs.2025.123376_bb0640","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneurol.2016.152","article-title":"Advances in markers of prodromal Parkinson disease","volume":"12","author":"Postuma","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.lfs.2025.123376_bb0645","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acn3.644","article-title":"The Parkinson\u2019s progression markers initiative (PPMI) \u2013 establishing a PD biomarker cohort","volume":"5","author":"Marek","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.lfs.2025.123376_bb0650","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1212\/WNL.0000000000004609","article-title":"Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls","volume":"89","author":"Mollenhauer","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.lfs.2025.123376_bb0655","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.drudis.2012.09.001","article-title":"Biomarkers of Parkinson\u2019s disease: current status and future perspectives","volume":"18","author":"Wang","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2025.123376_bb0660","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/s24051572","article-title":"Machine learning and digital biomarkers can detect early stages of neurodegenerative diseases","volume":"24","author":"Chudzik","year":"2024","journal-title":"Sensors"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525000098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525000098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T13:04:22Z","timestamp":1763039062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320525000098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":130,"alternative-id":["S0024320525000098"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123376","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciphering the role of neuropeptides as biomarkers for early diagnosis of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123376"}}